Clinic Valuation Guide 2026: How to Price Your Practice

TL;DR. Outpatient clinic valuations in 2026 run on adjusted EBITDA multiples, not revenue multiples or net income. Published ranges exist for dental (5-7x under $1M of EBITDA up to 11x+ above $5M, per FOCUS Investment Banking) and physical therapy (2.5-4x up to 6-8x+, per Breakwater M&A). For most other specialties no firm publishes a range it will stand behind. Most owners underprice their practice because they apply the wrong multiple to the wrong number, and the number is the part you can actually fix.

"I think it's worth about a million"

Take a dental practice doing $3.4M in collections with $660K of adjusted EBITDA once the owner's own production is normalised. The owner's accountant applies an old percentage-of-collections rule of thumb and calls it worth "about a million." Then a DSO shows up with an offer near $4.6M, and the owner's first instinct is that something must be off, because the number in his head is a million.

Run the arithmetic on a published ladder instead. At $660K of adjusted EBITDA the practice sits on FOCUS Investment Banking's under-$1M rung, which is 5-7x. Seven times $660K is $4.6M. The offer is not generous and it is not a trick; it is simply what the rung says. Percentage-of-collections has not been the standard methodology for outpatient practices in over a decade, and the gap between the two methods on the same numbers is most of the value of the business.

Most clinic owners I talk to either have never had a serious valuation done, or had one done years ago using a methodology that does not apply to today's market. They either accept low offers because they think their practice is worth less than it is, or reject reasonable offers because they think it is worth more. Both errors cost real money.

Here is how valuation actually works in 2026, with the four methodologies sophisticated buyers use, and where most owners get it wrong.

The four valuation methods (and which one matters)

There are four standard approaches to valuing a medical practice. They produce dramatically different numbers because they measure different things.

1. Asset-based valuation. Adds up the tangible assets (equipment, leasehold improvements, AR, supplies) and subtracts liabilities. A floor value, useful only for liquidation scenarios or asset-heavy practices. For a typical outpatient clinic it sits far below what the practice would actually transact at, because almost none of the value is in the equipment.

2. Revenue multiples. Practice value as a multiple of trailing twelve-month revenue. This was dominant twenty years ago and still used as a quick sanity check. Dangerous as a decision basis, because two practices with identical revenue can produce very different EBITDA depending on staffing efficiency, payer mix, and overhead.

3. EBITDA multiples (the current standard). Practice value as a multiple of adjusted earnings before interest, taxes, depreciation, and amortization. This is what every PE buyer, DSO, MSO, hospital system, and sophisticated strategic acquirer uses for outpatient practices in 2026. The multiple applied depends on specialty and on size, and platform deals price higher than add-ons — in general dentistry, FOCUS Investment Banking puts platform transactions at 9-11x EBITDA against 5-8x for add-ons. For specialty-specific ranges, see the breakdowns for dental practice EBITDA multiples, PT clinic EBITDA multiples, and med spa valuation.

4. Income approach (discounted cash flow). Projects future cash flows and discounts them to present value. Most accurate in theory but rarely used as the primary method in real transactions. It usually appears as a confirming methodology alongside EBITDA multiples rather than as the number the deal is struck on.

In any transaction of real size, the EBITDA multiple is what the price is actually built on. If your accountant is quoting you a number based on revenue multiples or asset value, they are using the wrong tool. Same with Seller's Discretionary Earnings (SDE), which is appropriate for practices under $2M where the buyer is a single practitioner, but irrelevant once you are talking to PE platforms or hospital systems.

Why owner-calculated EBITDA is almost always wrong

Here is where most owners leave the most money on the table.

The number on your P&L labeled "net income" is not your EBITDA. The EBITDA you would use as a starting point (net income plus interest, taxes, depreciation, amortization) is not adjusted EBITDA. And adjusted EBITDA is what the buyer is paying for.

Adjusted EBITDA is your EBITDA after a series of normalization adjustments that strip out non-recurring items, owner-specific spending, and below-market arrangements that a new owner would not inherit. The full list of what counts is covered in EBITDA add-backs in practice valuation. Done correctly, this number is usually higher than the one the owner has been quoting themselves.

The most common adjustments that move the number up:

Owner compensation above market. If you are paying yourself $450K in W-2 plus $200K in distributions plus benefits, but the market rate for a physician in your specialty is $350K all-in, that $300K gap is an EBITDA add-back. A new owner would only need to pay $350K to fill your clinical role.

Personal expenses run through the practice. Car leases, country club memberships, family cell phone plans, home office deductions on homes you barely work from, travel that is more leisure than business. These are legitimate tax deductions. They are also EBITDA add-backs in a valuation, and they are the category owners most often have never catalogued, because nothing in running the practice ever required them to.

One-time expenses. Lawsuit settlements, equipment replacement that will not recur, an office move, a software implementation. None of these belong in your normalized run-rate EBITDA.

Family on payroll. Your spouse who handles "marketing" but does not actually work full-time. Your son who works summers at $40K. These come off the cost base in normalization.

Below-market provider compensation that gets adjusted up. This works the opposite direction. If you pay an associate $180K to do work the market compensates at $250K, the buyer assumes the gap closes post-deal because the associate will otherwise leave. That $70K comes off your EBITDA.

Below-market rent. If you own the building and charge yourself $4K/month rent on a space that would lease at $9K market, the buyer adjusts rent up. That $60K/year reduces EBITDA. Most owners do not realize this works against them.

The first time an owner sees normalized EBITDA next to the figure they had in their head, the gap is usually the surprise of the meeting. Some adjustments will not survive due diligence. The net is still normally above where they started.

The 2026 multiples by specialty

Multiples are not constant. They vary by specialty, by practice size, by payer mix, by geography, and by whether you are a platform or an add-on acquisition.

Very few firms publish actual ranges. Two do, for two specialties, and both segment by adjusted EBITDA rather than by deal type:

Dental: FOCUS Investment Banking, December 2025, which also names the buyer at each rung, from small DSO tuck-ins at the bottom to platform buyers at the top. McLerran & Associates puts the same top rung at 10x to 12x+, though it attributes its table to market sources it does not name, so the FOCUS figure is the more traceable of the two.

Physical therapy: Breakwater M&A. As a whole-market cross-check, Peak Business Valuation puts physical therapy at 3.0x to 6.0x EBITDA without breaking it down by size.

For every other specialty, we could not find a firm that publishes a range it will stand behind. Not primary care, not dermatology, cardiology, ophthalmology, orthopedics, urgent care, mental health or med spa. Numbers for those circulate freely, but the ones we chased either had no source underneath them or traced back to another article quoting a third. So we are not printing them. If a broker quotes you a multiple for your specialty, the useful question is which transactions it came from and when.

What you can do instead is control the number the multiple gets applied to. Normalise your EBITDA properly, then get a range from an advisor who actually transacts in your specialty and can name the deals behind it.

Two things most owners miss.

First, the multiple expands as you scale, and you can see it in both sourced ladders above: dental moves from 5-7x under $1M of EBITDA to 11x+ above $5M, and physical therapy from 2.5-4x to 6-8x+. The same dollar of earnings is worth more once the practice is large enough to be bought as a platform rather than tucked into someone else's. That is why holding and growing sometimes beats selling now. Run your own figures in the dental practice valuation calculator or the physical therapy practice valuation calculator.

Second, specialty matters, but be careful how much weight you put on that. It is widely repeated that some specialties trade higher than others at the same EBITDA, and it is probably true. What is not available is a published, sourced table that tells you by how much. Adding a service line before a sale is an operating decision with real risk, and "the multiple expansion will cover it" is not a claim anyone has published the evidence for.

If you want to know where your practice lands on this table — using your adjusted EBITDA, not the net income on your P&L — take the free assessment. We will run the number with you.

What a PE buyer actually pays attention to

The multiple is not just a function of specialty and size. Buyers adjust the multiple they offer based on practice quality factors. Here is what moves your multiple up or down by 1-3 turns.

Multiple locations. A single-location practice trades at a discount to a 3-location practice at the same total EBITDA. Buyers see geographic concentration as risk.

Provider concentration. The more of the revenue the selling owner personally produces, the more of it a buyer treats as at risk the day that owner stops. Breakwater M&A puts a number on it for physical therapy: above 50% owner-generated revenue, a practice "may be valued closer to 2.5x to 3.5x EBITDA, regardless of other factors," and above roughly 20-25% buyers start requiring retention agreements or earnouts. Revenue spread across several providers prices better than revenue that walks out with the founder.

Payer mix. A strong commercial mix pulls the multiple higher. Heavy Medicaid exposure depresses it. Heavy Medicare exposure depresses it less, but still matters given the long-term reimbursement decline — and Medicare rates are set annually by rulemaking rather than negotiated, so that exposure is not something you can go and fix.

Revenue cycle quality. A practice with a high clean claim rate, tight days in AR, and a demonstrably small gap between billing and collections commands more than one where claims are reworked and balances stack up. Buyers diligence this directly, because it tells them how much of your reported revenue actually arrives.

Growth trajectory. Demonstrable trailing growth adds to the multiple. Flat or declining revenue subtracts, and a buyer will read the trend off the same monthly statements you use.

Clean financials. Location-level P&Ls, provider-level production reports, monthly financial statements going back 24-36 months, organized payer contracts. Having this organised does not by itself raise the price, but not having it is one of the most common reasons a deal slows, gets re-traded, or dies in diligence.

Real estate. If you own the practice real estate, you have optionality. You can sell the practice and lease back the building (sale-leaseback), or you can sell both together. Buyers typically prefer the sale-leaseback because it does not tie up their capital in real estate.

The four ways owners get the number wrong

When owners price their own practices, the same four mistakes come up over and over.

Using net income instead of adjusted EBITDA. Net income reflects your tax strategy, not your earning power. A practice that aggressively minimizes taxable income through legitimate strategies looks worse on net income but the same on adjusted EBITDA. Owners who apply a multiple to net income systematically lowball their own practice, sometimes by a wide margin.

Forgetting to add back personal expenses. Most owners have not catalogued the personal spending flowing through the practice. It is worth doing carefully, because the arithmetic compounds: at a 7x multiple, every $100K of legitimate add-backs you can document is $700K of enterprise value.

Ignoring the platform vs add-on distinction. The same practice prices differently depending on which one it is. In general dentistry, FOCUS Investment Banking puts platform transactions at 9-11x EBITDA against 5-8x for add-ons, and its ladder shows the buyer type changing as EBITDA grows. Reaching the size where platform buyers are the ones bidding can change the outcome materially.

Selling individually instead of as part of a group. Work it through on the dental ladder, where the rungs are published. Three practices each at $800K of adjusted EBITDA sit under $1M, so each prices at 5-7x. Combined into one group at $2.4M of EBITDA, the same earnings sit in the $1-3M rung at 7-9x, and a group past $5M reaches the top rung at 11x+. The earnings did not change. The rung did, and so did who is bidding.

What you should do if you are within 3 years of selling

If you might sell in the next 12-36 months, the work starts now. Even if you decide not to sell, preparing your practice for valuation is the same work that improves your operations.

Get a real valuation done. Not from your accountant unless your accountant specializes in healthcare M&A (most do not). Get a healthcare-specific advisor or fractional CFO to run normalized adjusted EBITDA, apply specialty-appropriate multiples, and give you a defensible value range. Ask what the fee covers and whether the multiple they apply comes with named comparable transactions behind it.

Clean up the financials. Move personal expenses out of the business. Normalize owner compensation. Fix your chart of accounts. Produce monthly financial statements with location-level P&Ls. Run provider-level profitability analysis so you can defend provider economics in due diligence.

Build the data room. Last 36 months of monthly financials. Payer contracts with current fee schedules. Provider compensation agreements. Lease agreements. Organizational chart. Quality and patient satisfaction data. Compliance documentation. The buyer will ask for all of this. Having it organized in advance accelerates the deal and demonstrates operational competence.

Diversify revenue. The more of the practice's revenue you personally produce, the more of it a buyer treats as at risk the day you stop. Breakwater M&A, writing about physical therapy, puts it concretely: above 50% owner-generated revenue a practice "may be valued closer to 2.5x to 3.5x EBITDA, regardless of other factors." Hiring or contracting additional providers is the fix, and it takes longer than most owners leave themselves.

Renegotiate commercial contracts. If you have not renegotiated in two years, the trailing 12-month EBITDA going into your sale will be lower than it could be. A rate increase carries straight to EBITDA, and every dollar of it is multiplied at exit.

The full timeline for a 12-18 month exit prep is laid out in selling your practice in 2027. The valuation work described here is the foundation everything else sits on.

The number that matters is not the number you have in your head

The single most expensive mistake a clinic owner can make is assuming they know what their practice is worth without rigorous analysis. Whether you are accepting a low offer because you think your practice is worth less, or rejecting a fair offer because you think it is worth more, the cost is the same: real money you will not get back.

If you want to know what your practice is actually worth using current 2026 multiples and proper EBITDA normalization, take the free assessment. Our fractional CFO services include valuation modeling, EBITDA normalization, and exit prep for owners who want a defensible number before they get the call.